| 7°C Dublin

Merck & Co Inc applies for US emergency use authorisation for drug to treat Covid-19

Close

Stock image

Stock image

Stock image

The American multinational pharmaceutical company Merck & Co Inc has applied for US emergency use authorisation for its drug to treat mild-to-moderate patients of Covid-19, putting it on course to become the first oral antiviral medication for the disease.

An authorisation from the US Food and Drug Administration FDA could help change clinical management of Covid-19 as the pill can be taken at home.

The treatment, Molnupiravir, cut the rate of hospitalisation and death by 50pc in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released earlier this month.

The interim efficacy data on the drug, developed with Ridgeback Biotherapeutics, had heavily dented the shares of Covid-19 vaccine makers and set off a scramble among nations, including Malaysia, South Korea and Singapore, to sign a supply deal with Merck.

The drugmaker has a US government contract to supply 1.7 million courses at a price of $700 per course.

Merck expects to produce 10 million courses of the treatment by the end of 2021.

It has also agreed to license the drug to several India-based generic drugmakers, which are expected to supply the treatment to more than 100 low- and middle-income countries.

Gilead Sciences Inc's infused antiviral Remdesivir is generally given only once a patient is hospitalised.

Daily Digest Newsletter

Get ahead of the day with the morning headlines at 7.30am and Fionnán Sheahan's exclusive take on the day's news every afternoon, with our free daily newsletter.

This field is required

Monoclonal antibody drugs from Regeneron Pharmaceuticals Inc and Eli Lilly which are typically infused as well, have so far seen only limited use due to the difficulty in administering them.

Merck's shares opened roughly 1pc higher before paring some gains to trade at $81.32.

Visit our Covid-19 vaccine dashboard for updates on the roll out of the vaccination program and the rate of Coronavirus cases Ireland


Most Watched





Privacy